Cantor Fitzgerald Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
Tweet Send to a Friend
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $163.00 price target on Sarepta Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
